Evolution of myocardial steatosis in high cardiovascular risk T2DM patients treated by GLP1 receptor agonists: LICAS study
We demonstrate a significant reduction in intramyocardial triglyceride content in patients with T2D after six months of treatment with GLP1-RA. The lack of correlation with reductions in HbA1c and BMI suggests a specific effect of GLP1-RA on myocardial steatosis, which might contribute to their previously demonstrated cardiovascular benefits.
Authors
- Charles Guénancia (ORCID: https://orcid.org/0000-0002-3554-7714)
- Paul M. Walker (ORCID: https://orcid.org/0000-0001-6693-3936)
- Thibault Leclercq (ORCID: https://orcid.org/0000-0002-9333-3896)
- Eléa Ksiazek (ORCID: https://orcid.org/0000-0003-3121-4899)
- Antoine Roger (ORCID: https://orcid.org/0000-0002-1865-5756)
- Isabelle Fournel (ORCID: https://orcid.org/0000-0002-3061-9715)
- Jean-Michel Petit
- Alexandre Cochet (ORCID: https://orcid.org/0009-0003-1747-8035)
- Isabelle Simoneau (ORCID: https://orcid.org/0000-0002-9092-1908)
- Benjamin Bouillet (ORCID: https://orcid.org/0000-0002-4317-6714)
- Lina Houbachi
Institutions
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Université de Bourgogne (FR)
- CHU Dijon Bourgogne (FR)
- Maison des Sciences sociales et des Humanités de Dijon (FR)
Publication Details
- Journal
- Diabetes Research and Clinical Practice
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1016/j.diabres.2025.112017
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.59